1-甲基-2-氧代-5-氨基吲哚啉 | 20870-91-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 吲哚类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-甲基-2-氧代-5-氨基吲哚啉
• 中文别名: 5-氨基-1-甲基-2-氧吲哚啉
• 英文名称: 5-amino-1-methyl-1,3-dihydro-2H-indol-2-one
• 英文别名: 5-amino-1-methyl-indolin-2-one；5-Amino-1-methyl-indolin-2-on；5-amino-1-methyl-1,3-dihydro-indol-2-one；5-amino-1-methylindolin-2-one；5-Amino-1-methyl-oxindol；5-Amino-N-methyl-oxindol；5-Amino-1-methyl-2-oxoindoline；5-amino-1-methyl-3H-indol-2-one
• CAS: 20870-91-1
• 化学式: C₉H₁₀N₂O
• mdl: MFCD09702413
• 分子量: 162.191
• InChiKey: ZGLUKQQSWABKDH-UHFFFAOYSA-N

物化性质

• 熔点：
  109 °C
• 沸点：
  472℃
• 密度：
  1.263
• 闪点：
  239℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933790090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302+H312+H332,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Amino-1-methyl-2-oxoindoline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Amino-1-methyl-2-oxoindoline
CAS number: 20870-91-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H10N2O
Molecular weight: 162.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  N-甲基吲哚酮	N-methyl-2-indolinone	61-70-1	C9H9NO	147.177
  5-溴-1,3-二氢-吲哚-2-酮	1-methyl-5-nitro-1,3-dihydro-indol-2-one	20870-89-7	C9H8N2O3	192.174

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	(2R)-2-hydroxy-3-(1-methyl-2-oxo-2,3-dihydro-1H-indol-5-ylamino)-propionic acid methyl ester	875003-39-7	C13H16N2O4	264.281
  ——	(R)-[2-hydroxy-3-(1-methyl-2-oxo-2,3-dihydro-1H-indol-5-ylamino)-propyl]-carbamic acid tert-butyl ester	911919-12-5	C17H25N3O4	335.403
  5-溴-1-甲基-2-氧吲哚烷	5-bromo-1-methyl-1,3-dihydro-indol-2-one	20870-90-0	C9H8BrNO	226.073

反应信息

• 作为反应物：
  描述：

  1-甲基-2-氧代-5-氨基吲哚啉 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 3-[6-[[(3S,4R)-1-[5-chloro-4-[(1-methyl-2-oxoindolin-5-yl)amino]pyrimidin-2-yl]-3-(hydroxymethyl)-4-piperidyl]amino]-1-methylindazol-3-yl]piperidine-2,6-dione
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS
  [FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QUE MODULATEURS DE BCL6 À UTILISER EN TANT QU'AGENTS DE DÉGRADATION DIRIGÉS CONTRE UN LIGAND

  摘要：

  本文提供了用于调节 BCL6 的化合物及其组合物。在某些实施方案中，这些化合物和组合物用于治疗癌症或自身免疫性疾病。

  公开号：

  WO2023212147A1
• 作为产物：
  描述：

  5-溴-1,3-二氢-吲哚-2-酮 在 铁粉 、 氯化铵 作用下， 以 乙醇 、 水 为溶剂， 反应 0.5h， 生成 1-甲基-2-氧代-5-氨基吲哚啉
  参考文献：
  名称：

  Oxazolidinones containing oxindoles as antibacterial agents

  摘要：

  本发明涉及一种新的氧化吲哚氧杂环丙酮衍生物，其化学式为I，或其药学上可接受的盐，其中Y1为—CH—或—CF—；R1为—C1-4烷基，可选择地用氟原子取代，或R1为—C3-5环烷基；以及R2为—H或—CH3。这些化合物可用作抗菌剂。

  公开号：

  US20060030609A1

文献信息

• Oxazolidinones containing oxindoles as antibacterial agents
  申请人：Luehr W. Gary

  公开号：US20060030609A1

  公开（公告）日：2006-02-09

  The present invention relates to novel oxazolidinones derivatives of oxindoles of formula I, or a pharmaceutically acceptable salt thereof wherein Y 1 is —CH— or —CF—; R 1 is —C 1-4 alkyl, optionally substituted with a fluoro atom, or R 1 is —C 3-5 cycloalkyl; and R 2 is —H or —CH 3 . These compounds are useful as antibacterial agents.

  本发明涉及一种新的氧化吲哚氧杂环丙酮衍生物，其化学式为I，或其药学上可接受的盐，其中Y1为—CH—或—CF—；R1为—C1-4烷基，可选择地用氟原子取代，或R1为—C3-5环烷基；以及R2为—H或—CH3。这些化合物可用作抗菌剂。
• Zinc triflate-mediated cyclopropanation of oxindoles with vinyl diphenyl sulfonium triflate: a mild reaction with broad functional group compatibility
  作者：Mingwei Zhou、Ke En、Yimin Hu、Yufang Xu、Hong C. Shen、Xuhong Qian

  DOI：10.1039/c6ra24985j

  日期：——

  oxindoles with vinyl diphenyl sulfonium triflate salt is reported. The reaction proceeded under ambient conditions and consistently provided high yields with broad functional group tolerability. The utility for the late-stage functionalization (LSF) of complex molecules is demonstrated.

  据报道，三氟甲磺酸锌首次用于将未保护的羟吲哚与乙烯基二苯基三氟甲磺酸salt盐环丙烷化。反应在环境条件下进行，并始终提供高收率和宽泛的官能团耐受性。证明了可用于复杂分子的后期功能化（LSF）。
• [EN] NOVEL KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060113A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种具有公式（I）的新化合物，能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物在治疗多种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
• [EN] SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS<br/>[FR] DÉRIVÉS SUBSTITUÉS DE L'ACIDE ARYLSULFONYLAMINOMÉTHYLPHOSPHONIQUE, LEUR PRÉPARATION ET LEUR UTILISATION POUR TRAITER LE DIABÈTE SUCRÉ DE TYPE I ET DE TYPE II
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009016119A1

  公开（公告）日：2009-02-05

  The present invention relates to substituted arylsulphonylaminomethylphosphonic acid derivatives of general formula (I) wherein R, X, Y and Z are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof which have valuable pharmacological properties, particularly the suppression of the interaction of glycogen phosphorylase a with the GL subunit of glycogen-associated protein phosphatase 1 (PP1), and their use as pharmaceutical compositions.

  本发明涉及一般式(I)的取代芳基磺酰氨甲基膦酸衍生物，其中R、X、Y和Z如权利要求书中所定义，其互变异构体、对映体、非对映体、它们的混合物及其盐具有有价值的药理特性，特别是抑制糖原磷酸化酶a与糖原相关蛋白磷酸酶1（PP1）的GL亚基的相互作用，并将其用作药物组成物。
• Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors
  作者：Rajeev S. Bhide、Alec Keon、Carolyn Weigelt、John S. Sack、Robert J. Schmidt、Shuqun Lin、Hai-Yun Xiao、Steven H. Spergel、James Kempson、William J. Pitts、Julie Carman、Michael A. Poss

  DOI：10.1016/j.bmcl.2017.09.029

  日期：2017.11

  The identification of small molecule inhibitors of IRAK4 for the treatment of autoimmune diseases has been an area of intense research. We discovered novel 4,6-diaminonicotinamides which potently inhibit IRAK4. Optimization efforts were aided by X-ray crystal structures of inhibitors bound to IRAK4. Structure activity relationship (SAR) studies led to the identification of compound 29 which exhibited

  识别用于治疗自身免疫性疾病的IRAK4的小分子抑制剂一直是研究的热点。我们发现了有效抑制IRAK4的新型4，6-二氨基烟酰胺。与IRAK4结合的抑制剂的X射线晶体结构有助于优化工作。结构活性关系（SAR）研究导致鉴定了在LTA刺激的细胞分析中表现出亚微摩尔效价的化合物29。